Changzhou Qianhong Biopharma Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. is a leading production and operation enterprise in the domestic biochemical pharmaceutical industry for polysaccharide and protease drugs, a national high-tech enterprise, and a key backbone enterprise of the national three drug base. It has been awarded the title of National, Provincial, and Municipal Drug Quality Integrity Demonstration Enterprise for many consecutive years. On February 18, 2011, it was successfully listed on the Shenzhen Stock Exchange. Currently, it has four holding subsidiaries: Jiangsu Zhonghong Biotechnology Innovation and Drug Research Institute Co., Ltd. (referred to as Zhonghong Biotechnology), Changzhou Yingnuoshengkang Biopharmaceutical Technology Co., Ltd. (referred to as Yingnuoshengkang), Hubei Runhong Biotechnology Co., Ltd. (referred to as Hubei Runhong), and Changzhou Qianhong Health Technology Co., Ltd. (referred to as Qianhong Health). Our company's main products include pancreatic kininogenase series, heparin sodium and low molecular weight heparin series, compound digestive enzyme preparations, and asparaginase series, all of which are pioneering in China. Our production technology and quality level have reached advanced international and domestic levels. Multiple products have passed quality certifications organized by governments in the United States, the European Union, Japan, and other countries. The company has established a comprehensive domestic and international marketing network system, with products covering more than 20 provinces and cities across the country, and exported to international markets such as Europe, America, and Japan. The company has established the Changzhou Qianhong International Biopharmaceutical Innovation Drug Incubation Base, and has an advanced research and development platform in the industry. Major progress has been made in the research of multiple gene recombinant protein drugs, targeted anti-tumor drugs, etc., and multiple Class I new drugs have entered human clinical trials; At the same time, we have also undertaken multiple national and provincial level major scientific and technological research and development projects, providing strong core competitiveness for the company's development and growth. Looking forward to the future, the company will adhere to the development strategy of "focusing on the field of biopharmaceuticals, guiding core competitiveness with innovative drugs, deeply cultivating the domestic pharmaceutical market and exporting high value-added varieties", and strive to become a first-class and competitive large-scale biopharmaceutical enterprise in China. |
| Headquarter | Changzhou |
| Establish Date | 4/30/2003 |
| Listed Code | 002550.SZ |
| Listed Date | 2/18/2011 |
| Chairman | Wang Yaofang. |
| CEO | Wang Ke. |
| Website | www.qhsh.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
